MIL62, an injection therapy approved exclusively in China for neuromyelitis optica spectrum disorder (NMOSD), was found to keep most NMOSD patients free of relapses for up to two years, while being generally safe and well tolerated. That’s according to data from the Phase 1b portion of a single-center…
Discussion
I’ve never been great at fitting neatly into so-called boxes, especially spiritual ones. I grew up exposed to many religions, from Jehovah’s Witnesses to Seventh-day Adventists. I even begged my mom to send me to Catholic school for a period during elementary school, and dragged my younger brother along. In…
An international team of researchers has identified three genetic variants significantly associated with higher odds of developing neuromyelitis optica spectrum disorder (NMOSD) with self-reactive antibodies against the AQP4 protein. The data also suggest that, in terms of genetic risk factors, AQP4-positive NMOSD is more similar to systemic autoimmune diseases…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
